Linagliptin

Anarana simika:

8-[(3R)-3-aminopiperidin-1-yl]-7-(fa-2-yn-1-yl)-3- methyl-1-[(4-methylquinazolin-2-yl)methyl]-3 ,7-dihydro-1H-purine-2,6-dione

Kaody SMILES:

O=C(N1CC2=NC(C)=C3C=CC=CC3=N2)N(C)C4=C(N(CC#CC)C(N5C[C@H](N)CCC5)=N4)C1 =O

InChi Code:

InChI=1S/C25H28N8O2/c1-4-5-13-32-21-22(29-24(32)31-12-8-9-17(26)14-31)30(3)25(35) 33(23(21)34)15-20-27-16(2)18-10-6-7-11-19(18)28-20/h6-7,10-11,17H,8-9, 12-15,26H2,1-3H3/t17-/m1/s1

InChi Key:

LTXREWYXXSTFRX-QGZVFWFLSA-N

Keyword:

Linagliptin, BI-1356, BI 1356, BI1356, 668270-12-0

Solubility:Mety levona amin'ny DMSO

fitahirizana:0 - 4°C mandritra ny fotoana fohy (andro na herinandro), na -20°C mandritra ny fotoana maharitra (volana).

Famaritana:

Linagliptin, fantatra ihany koa amin'ny anarana hoe BI-1356, dia inhibitor DPP-4 novolavolain'i Boehringer Ingelheim ho fitsaboana ny diabeta karazany II. Linagliptin (indray mandeha isan'andro) dia nankatoavin'ny US FDA tamin'ny 2 May 2011 ho fitsaboana ny diabeta karazany II. Izy io dia mivarotra an'i Boehringer Ingelheim sy Lilly.

Tanjona: DPP-4